Pathophysiological aspects of hyperglycemia in children with meningococcal sepsis and septic shock

Submission date	Recruitment status	Prospectively registered
22/06/2010	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
07/07/2010	Completed	Results
Last Edited	Condition category	Individual participant data
07/07/2010	Infections and Infestations	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Koen Joosten

Contact details

Dr Molewaterplein 60 Rotterdam Netherlands 3000CB

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 196429 / 2000 / 222

Study information

Scientific Title

Pathophysiological aspects of hyperglycemia in children with meningococcal sepsis and septic shock: a prospective, observational cohort study

Study objectives

The objective of the present study was to investigate the occurrence of hyperglycemia in relation with the insulin response and exogenous factors, such as glucose intake and drug use, in a homogenous group of critically ill children with meningococcal sepsis and/or meningococcal septic shock.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Medical Ethics Committee (MEC) approved in March 2000 (ref: 196429 / 2000 / 222)

Study design

Prospective observational cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Meningococcal sepsis

Interventions

Observational cohort study. Blood samples to be taken on admission, and at 24 and 48 hours thereafter.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

- 1. Blood glucose levels
- 2. Plasma levels of

- 2.1. insulin
- 2.2. C-peptide
- 2.3. cortisol
- 2.4. cytokines
- 2.5. C-reactive protein (CRP)
- 2.6. cytokines

Measured on admission, and at 24 and 48 hours.

Secondary outcome measures

None

Overall study start date

01/10/1997

Completion date

01/05/2004

Eligibility

Key inclusion criteria

The study population consisted of previously healthy children admitted to the Pediatric Intensive Care Unit (PICU) of the Erasmus Medical Centre - Sophia Childrens Hospital between October 1997 and May 2004, suffering from meningococcal sepsis, i.e. sepsis with petechiae /purpura

Participant type(s)

Patient

Age group

Child

Sex

Both

Target number of participants

80

Key exclusion criteria

- 1. Pre-existing endocrine or chromosomal abnormalities
- 2. Radiation or chemotherapy within the previous 6 months

Date of first enrolment

01/10/1997

Date of final enrolment

01/05/2004

Locations

Countries of recruitment

Study participating centre
Dr Molewaterplein 60
Rotterdam
Netherlands
3000CB

Sponsor information

Organisation

Erasmus Medical Centre, Sophia Childrens Hospital (Netherlands)

Sponsor details

Dr Molewaterplein 60 Rotterdam Netherlands 3000CB

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/047afsm11

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Erasmus Medical Centre, Sophia Childrens Hospital (Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration